Home > Boards > US OTC > Biotechs > Inspyr Therapeutics Inc. (NSPX)

I agree with you, it is not listed

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
chrislal Member Profile
 
Followed By 16
Posts 1,153
Boards Moderated 0
Alias Born 06/03/13
160x600 placeholder
chrislal   Thursday, 10/03/19 11:11:52 PM
Re: DojiMan post# 9140
Post # of 9325 
I agree with you, it is not listed at OTC. But there were 150 million and after the RS, it is
6 million. Here is the copy/paste from my brokerage page showing the count.

nspyr Therapeutics Inc
OTC Pink - Current Information:NSPXDUnited States
Search Name or Symbol
Enter Name or Symbol
Search
As of 2019-10-03 at 11:00:34 PM ET
RefreshPrintHelp Documentation
Collapse Quote Bar
LAST PRICE
0.03
TODAY'S CHANGE (%)
0.00 (0.00%)

As of 2019-10-03
COMPANY INFORMATION
Inspyr Therapeutics, Inc., formerly GenSpera, Inc., is an integrated biopharmaceutical company. The Company is focused on the development of therapies to treat cancer, inflammation, and other diseases. It operates a technology platform based on adenosine chemistry and biology. Its product pipeline includes Mipsagargin; A2A antagonist; A2B antagonist; A2A agonist, and A2A/A2B Dual Antagonist. The Company is developing Mipsagargin for different tumor types, including Hepatocellular carcinoma (liver cancer), Glioblastoma (brain cancer) and Prostate cancer. The other combinations of Mipsagargin include PD1/PDL1 combination and Xenograft models. The A2A antagonist; A2B antagonist; A2A agonist, and A2A/A2B dual antagonist are its adenosine receptor programs.

Contact Information
Headquarters2511 N Loop 1604 W Ste 204SAN ANTONIO, TX, United States 78258-4635
Phone210-479-8112
Fax210-479-8113
Executives
Interim Chief Executive Officer, DirectorMichael Cain
DirectorJohn Montgomery
DirectorClaire Thom
Independent DirectorScott Ogilvie
RATINGS
Please note that US and Canadian reports and ratings may both appear in this module for interlisted securities. The green highlighted bar represents the First Call Consensus rating.

No data available
At 2019-10-03 11:00 PM ET
REPORTS
Documents not available0 New Today
FUNDAMENTALS
Fundamentals Table
Market Cap
$180.0K
Revenue (TTM)
$0.00
Shares Outstanding
6.0M
Inspyr Therapeutics Inc does not pay a dividend.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist